Fractyl Health Focuses on Revita, Discontinues Rejuva Development
Fractyl Health will advance its Revita therapy toward an FDA De Novo submission based on positive clinical data while discontinuing its Rejuva gene therapy. This strategic shift includes a workforce reduction to extend cash runway into 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed